DHR broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 42 similar instances where the stock broke above the upper band. In 27 of the 42 cases the stock fell afterwards. This puts the odds of success at 64%.
The 10-day RSI Indicator for DHR moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 similar instances where the indicator moved out of overbought territory. In 13 of the 29 cases, the stock moved lower in the following days. This puts the odds of a move lower at 45%.
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 59%.
The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on DHR as a result. In 57 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 64%.
The Moving Average Convergence Divergence (MACD) for DHR just turned positive on October 14, 2026. Looking at past instances where DHR's MACD turned positive, the stock continued to rise in 25 of 47 cases over the following month. The odds of a continued upward trend are 53%.
Following a +3.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DHR advanced for three days, in 174 of 319 cases, the price rose further within the following month. The odds of a continued upward trend are 55%.
The Aroon Indicator entered an Uptrend today. In 111 of 199 cases where DHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 56%.
The Tickeron Price Growth Rating for this company is 14 (best 1 - 100 worst), indicating outstanding price growth. DHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.127) is normal, around the industry mean (66.046). P/E Ratio (41.465) is within average values for comparable stocks, (2.422). Projected Growth (PEG Ratio) (1.361) is also within normal values, averaging (3.473). Dividend Yield (0.007) settles around the average of (0.002) among similar stocks. P/S Ratio (5.900) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 53 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 77 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The 10-day moving average for QDEL crossed bullishly above the 50-day moving average on October 16, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on October 02, 2026. You may want to consider a long position or call options on QDEL as a result. In 56 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 65%.
The Moving Average Convergence Divergence (MACD) for QDEL just turned positive on September 28, 2026. Looking at past instances where QDEL's MACD turned positive, the stock continued to rise in 33 of 49 cases over the following month. The odds of a continued upward trend are 67%.
QDEL moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +9.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where QDEL advanced for three days, in 177 of 262 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The 10-day RSI Indicator for QDEL moved out of overbought territory on October 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In 18 of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where QDEL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
QDEL broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for QDEL entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 21 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.521) is normal, around the industry mean (2.874). P/E Ratio (-0.874) is within average values for comparable stocks, (2.324). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (0.274) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 45 (best 1 - 100 worst), indicating steady price growth. QDEL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. QDEL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
DHR | QDEL | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 30 | 18 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 18 Undervalued | 36 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 77 | 98 | |
PRICE GROWTH RATING 1..100 | 14 | 45 | |
P/E GROWTH RATING 1..100 | 53 | 21 | |
SEASONALITY SCORE 1..100 | 50 | 42 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (18) in the Medical Specialties industry is in the same range as QDEL (36). This means that DHR’s stock grew similarly to QDEL’s over the last 12 months.
DHR's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as QDEL (100). This means that DHR’s stock grew similarly to QDEL’s over the last 12 months.
DHR's SMR Rating (77) in the Medical Specialties industry is in the same range as QDEL (98). This means that DHR’s stock grew similarly to QDEL’s over the last 12 months.
DHR's Price Growth Rating (14) in the Medical Specialties industry is in the same range as QDEL (45). This means that DHR’s stock grew similarly to QDEL’s over the last 12 months.
QDEL's P/E Growth Rating (21) in the Medical Specialties industry is in the same range as DHR (53). This means that QDEL’s stock grew similarly to DHR’s over the last 12 months.
| DHR | QDEL | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 45% | 1 day ago 90% |
| Stochastic ODDS (%) | 1 day ago 60% | 1 day ago 85% |
| Momentum ODDS (%) | 1 day ago 64% | 1 day ago 65% |
| MACD ODDS (%) | 1 day ago 53% | 1 day ago 67% |
| TrendWeek ODDS (%) | 1 day ago 62% | 1 day ago 82% |
| TrendMonth ODDS (%) | 1 day ago 57% | 1 day ago 69% |
| Advances ODDS (%) | 8 days ago 55% | 14 days ago 68% |
| Declines ODDS (%) | 3 days ago 59% | 1 day ago 80% |
| BollingerBands ODDS (%) | 1 day ago 64% | 1 day ago 79% |
| Aroon ODDS (%) | 1 day ago 56% | 1 day ago 82% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 2 FA rating(s) are green while QDEL’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 4 TA indicator(s) are bullish while QDEL’s TA Score has 5 bullish TA indicator(s).
DHR (@Medical Specialties) experienced а +4.08% price change this week, while QDEL (@Medical/Nursing Services) price change was +1.51% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -3.15%. For the same industry, the average monthly price growth was -6.50%, and the average quarterly price growth was +42.74%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -1.62%. For the same industry, the average monthly price growth was -10.72%, and the average quarterly price growth was -10.29%.
DHR is expected to report earnings on Feb 03, 2027.
QDEL is expected to report earnings on Nov 03, 2026.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-1.62% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | -1.76% | ||
| TMO - DHR | 73% Closely correlated | -2.52% | ||
| RGEN - DHR | 68% Closely correlated | -0.72% | ||
| BIO - DHR | 64% Loosely correlated | +0.83% | ||
| A - DHR | 60% Loosely correlated | -2.17% | ||
| BRKR - DHR | 58% Loosely correlated | -3.04% | ||
More | ||||
A.I.dvisor indicates that over the last year, QDEL has been loosely correlated with AZTA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if QDEL jumps, then AZTA could also see price increases.
| Ticker / NAME | Correlation To QDEL | 1D Price Change % | ||
|---|---|---|---|---|
| QDEL | 100% | -4.26% | ||
| AZTA - QDEL | 51% Loosely correlated | -2.04% | ||
| XRAY - QDEL | 50% Loosely correlated | +4.63% | ||
| RVTY - QDEL | 50% Loosely correlated | +0.48% | ||
| DHR - QDEL | 49% Loosely correlated | -1.76% | ||
| A - QDEL | 48% Loosely correlated | -2.17% | ||
More | ||||